Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).
National Immunisation Programme: new decline in number of reported cases of disease in 2021 In 2021, fewer people contracted diseases for which vaccines are offered under the National Immunisation Programme (NIP) than before the coronavirus pandemic. This is very likely largely due to the impact of the coronavirus measures, such as social distancing and hand washing.
Patient with cutaneous diphtheria in reception centre This week, a refugee from Syria was found to be infected with the diphtheria bacterium. The patient has been treated with antibiotics. The patient’s contacts have been tested and vaccinated.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
New test for Lyme disease is not reliable To determine whether someone has Lyme disease, doctors in the Netherlands often use antibody tests. For some time now, so-called cellular tests have been available on the market.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.